Literature DB >> 15008879

Cutaneous seeding of hepatocellular carcinoma due to percutaneous ethanol injection and masquerading as a pyogenic granuloma.

Mei-Ching Lee1, Yau-Li Huang, Chih-Hsun Yang, Tseng-tong Kuo, Hong-Shang Hong.   

Abstract

BACKGROUND: This investigation reports a 68-year-old man with a history of hepatocellular carcinoma (HCC) diagnosed 2 years previously who developed a single, easy-bleeding, pyogenic granuloma (PG)-like lesion on his right upper abdomen, located in the area of previous therapeutic percutaneous ethanol injection (PEI) for HCC treatment. The lesion developed 3 months after the injection. The tumor was found to be identical to his previous HCC.
OBJECTIVE: To describe a case of cutaneous seeding of HCC during PEI presented as a PG-like lesion. To our knowledge, this is the first such case reported in the literature.
METHODS: This is a case report and review the literature.
RESULTS: Immunostainings for alpha-fetoprotein and hepatocyte monoclonal antibody confirmed the diagnosis. Besides, the patient had no other metastatic lesion.
CONCLUSION: This tumor is believed to be caused by cutaneous seeding of HCC during PEI and is simulated clinically as a PG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008879     DOI: 10.1111/j.1524-4725.2004.30120.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Cutaneous metastases of visceral tumours: a review.

Authors:  Dorothée Nashan; Marcel Lucas Müller; Markus Braun-Falco; Sebastian Reichenberger; Rolf-Markus Szeimies; Leena Bruckner-Tuderman
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

2.  Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood.

Authors:  L Zachau; C Zeckey; J Schlue; J Sander; C Meyer-Heithuis; M Winkler; J Klempnauer; H Schrem
Journal:  World J Surg Oncol       Date:  2012-05-30       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.